Movatterモバイル変換


[0]ホーム

URL:


ECSP982720A - FORMULATION CONTAINING AN OPIOID IN COMBINATION WITH AN ADRENERGIC AGONIST AND ITS USE AS AN ANALGESIC - Google Patents

FORMULATION CONTAINING AN OPIOID IN COMBINATION WITH AN ADRENERGIC AGONIST AND ITS USE AS AN ANALGESIC

Info

Publication number
ECSP982720A
ECSP982720AECSP982720AECSP982720AEC SP982720 AECSP982720 AEC SP982720AEC SP982720 AECSP982720 AEC SP982720AEC SP982720 AECSP982720 AEC SP982720A
Authority
EC
Ecuador
Prior art keywords
opioid
adrenergic agonist
analgesic
combination
formulation containing
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Johannes Schneider
Johanna Korioth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP982720priorityCriticalpatent/ECSP982720A/en
Publication of ECSP982720ApublicationCriticalpatent/ECSP982720A/en

Links

Landscapes

Abstract

Translated fromSpanish

Formulación que contiene un opioide en combinación con un agonista alfa-adenérgico o sales farmacéuticamente aplicables de las sustancias activas y otros excipientes, en que para el agonista alfa-adrenérgicos se utiliza la unidad de dosificación entre 1ug y 500ug, y para el opioide la unidad de dosificación entre 0.5 y 50 mg. evitando la formulación de efectos circulatorios de origen central, y la utilización como analgésico.Formulation containing an opioid in combination with an alpha-adrenergic agonist or pharmaceutically applicable salts of the active substances and other excipients, in which the dosage unit between 1ug and 500ug is used for the alpha-adrenergic agonist, and for the opioid unit dosage between 0.5 and 50 mg. avoiding the formulation of circulatory effects of central origin, and the use as an analgesic.

ECSP9827201998-10-301998-10-30 FORMULATION CONTAINING AN OPIOID IN COMBINATION WITH AN ADRENERGIC AGONIST AND ITS USE AS AN ANALGESICECSP982720A (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
ECSP982720ECSP982720A (en)1998-10-301998-10-30 FORMULATION CONTAINING AN OPIOID IN COMBINATION WITH AN ADRENERGIC AGONIST AND ITS USE AS AN ANALGESIC

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
ECSP982720ECSP982720A (en)1998-10-301998-10-30 FORMULATION CONTAINING AN OPIOID IN COMBINATION WITH AN ADRENERGIC AGONIST AND ITS USE AS AN ANALGESIC

Publications (1)

Publication NumberPublication Date
ECSP982720Atrue ECSP982720A (en)1999-04-21

Family

ID=42043638

Family Applications (1)

Application NumberTitlePriority DateFiling Date
ECSP982720ECSP982720A (en)1998-10-301998-10-30 FORMULATION CONTAINING AN OPIOID IN COMBINATION WITH AN ADRENERGIC AGONIST AND ITS USE AS AN ANALGESIC

Country Status (1)

CountryLink
EC (1)ECSP982720A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US9901540B2 (en)2010-05-102018-02-27Euro-Celtique S.A.Combination of active loaded granules with additional actives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US9901540B2 (en)2010-05-102018-02-27Euro-Celtique S.A.Combination of active loaded granules with additional actives

Similar Documents

PublicationPublication DateTitle
UY25242A1 (en) BENZOTIAZOLE INHIBITORS OF PROTEIN THYROSINE KINASE
ES2162517T3 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMBINATION OF METFORMIN AND FIBRATE AND ITS USE IN THE PREPARATION OF DRUGS INTENDED TO REDUCE HYPERGLYCEMIA.
AR038527A1 (en) DOSAGE FORM CONTAINING A PDE 4 INHIBITOR AS ACTIVE INGREDIENT
ES2185816T3 (en) FORMS OF PHARMACEUTICAL DOSAGE FOR THE ORAL ROUTE, WHICH INCLUDE AN INHIBITING AGENT OF THE PUMP OF PROTONS AND A PROCEDURAL AGENT.
ES2167061T3 (en) DOSAGE FORMS TO IMPROVE ERECTILE DYSFUNCTION IN MALE SEX PATIENTS.
AR005281A1 (en) ORAL PHARACEUTICAL COMPOSITION, PROCEDURES FOR ITS MANUFACTURE AND USE OF THAT PHARMACEUTICAL COMPOSITION FOR THE PREPARATION OF MEDICINES. .
CL2010000816A1 (en) Formulation suitable for subcutaneous administration comprising at least 100 mg / ml of ctlaig, a sugar, and a pharmaceutically stable aqueous carrier; article of manufacture comprising at least one container containing the aforementioned formulation. (divisional application n ° 3597-06)
ES2157944T3 (en) CORES OF IMMEDIATE RELEASE PADS OF INSOLUBLE MEDICINES THAT HAVE A COVER OF SUSTAINED RELEASE.
CO5011096A1 (en) MEDICINES CONTAINING ANTAGONISTS OF THE 5-HT3 RECEPTOR FOR THE TREATMENT OF IBS
CO5271759A1 (en) FORMULATION IN SOLUTION CONTAINING A MIXTURE OF SOLVENTS
ECSP066365A (en) ANILINO PURINAS REPLACED IN POSITION 6 USEFUL AS RTK INHIBITORS
PT957914E (en) FORMULATION OF 5-HT AGONISTS
PT1267832E (en) AUTO-EMULSIFYING SYSTEM OF LIBERATION OF PHARMACO
ES2093735T3 (en) MELATONIN DERIVATIVES FOR USE IN SLEEP DISORDERS THERAPY AND IN PRE-ANESTHETIC MEDICATION.
HN2004000232A (en) "PIRROLO DERIVATIVES (3,4-C) PIRAZOL ACTIVE AS QUINASE INHIBITORS, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM."
NI200500087A (en) DERIVATIVES 4-TETRAZOLYL-4 PHENYLPIPERIDINE FOR PAIN TREATMENT
UY25544A1 (en) NEFAZODONE DOSAGE FORM
AR099437A2 (en) MATRIX FOR SUSTAINED, INVARIABLE AND INDEPENDENT RELEASE OF ACTIVE COMPOUNDS
ID28510A (en) NEW ORAL FORMULATION FOR AGONISTS OR 5-HT4 ANTAGONISTS
PE123899A1 (en) FORMULATION CONTAINING AN OPIOID IN COMBINATION WITH AN ALPHA-ADRENERGIC AGONIST AND ITS USE AS AN ANALGESIC
BR0008468A (en) Method for human in vitro fertilization, use of a hypothalamic hormone and / or pituitary hormone or an agonist or antagonist of the same or an active derivative thereof, pharmaceutical kit in single dosage form, and any new aspect or combination of aspects
AR018607A1 (en) PHARMACEUTICAL PREPARATION THAT IN QUALITY OF ACTIVE INGREDIENT CONTAINS SODIUM LEVOTIROXIN, AND A PROCEDURE FOR ITS PREPARATION
BR0015225A (en) Emphysema treatment using selective retinoid antagonists to rar
ES2195538T3 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMBINATION OF ISOMEROS DEXTRO AND LEVO DE SOTALOL.
CL2002001701A1 (en) Use of at least one compound selected from melatonin, melatoninergic agents, melatonin agonists and antagonists, in an amount of 0.0025-50 mg, to prepare a useful medicine for the treatment and improvement of the restorative quality of sleep.

[8]ページ先頭

©2009-2025 Movatter.jp